ClinicalTrials.gg
RecruitingNCT05598671Updated Feb 28, 2024

Percutaneous Nephrolithotomy Without a Ureteral Catheter

An interventional study of PCNL without reverse insertion of a ureteral catheter in Nephrolithotomy Percutaneous and Kidney Calculi, sponsored by The First Affiliated Hospital of University of South China. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by The First Affiliated Hospital of University of South China · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Conventional Percutaneous nephrolithotomy (PCNL) surgery requires the patient to first undergo retrograde transurethral ureteroscopic insertion of the ureteral catheter in the lithotomy position, and then change the patient to the prone position. However, repeated operation on the ureter can bring about immediate and long-term negative effects, such as ureteral false way formation, ureteral damage, perforation, avulsion, catheter insertion into the vena cava, pricking the kidney, increased postoperative pain, urinary extravasation, scar formation, and ureteral narrowing. The study planned to perform the operation in the prone position without reverse insertion of a ureteral catheter in the PCNL surgery.

Read the detailed description

The purpose of this single-center, single-blind, randomized trial was to evaluate the safety and efficacy of PCNL without reverse insertion of a ureteral catheter. It is planned to start in November 2022 and is expected to end in November 2024. Based on inclusion and exclusion criteria, 200 subjects were expected to be recruited. In a parallel group design, subjects were randomly assigned to two groups: the experimental group received PCNL without reverse insertion of a ureteral catheter , and the control group received traditional PCNL. The primary end point of the study was the incidence of postoperative complications according to the modified Clavien-Dindo complication grading system. Secondary end points included Stone-free rate, operation time, length of hospital stay, and medical costs. Measurement data were expressed as mean ± standard deviation (X ± S), and Student's t-test was used for intergroup comparisons. The counting data were expressed as frequency and percentage, and the chi-squared or Fisher's exact probability test were used for intergroup comparisons. The rank-sum test was used for grade data. P\<0.05 was considered statistically significant.

02

Conditions studied

  • Nephrolithotomy Percutaneous
  • Kidney Calculi

Browse trials for

03

In context

Kidney Calculi

509 studies on the registry are indexed under Kidney Calculi; 146 are open to participants now.

This study's planned enrollment of 200 is above the median of 86 across 391 interventional studies indexed under Kidney Calculi.

Browse Kidney Calculi studies →

Lead sponsor

The First Affiliated Hospital of University of South China is the lead sponsor of 13 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with upper urinary tract stones who were 18 years of age or older and eligible for PCNL surgery.

Exclusion criteria

Exclusion Criteria:

  • patients with infectious calculi confirmed by preoperative CT examination and blood biochemical indexes.
  • Patients with severe cardiac and pulmonary insufficiency, coagulation dysfunction and other obvious surgical .
  • Patients with previous history of PCNL surgery on the affected side or nephrotomy.
  • Patients with indwelling double J tube or nephrostomy tube before operation.
  • Patients with renal trauma or congenital anomalies of urinary system.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    without reverse insertion of a ureteral catheter

    Percutaneous nephrolithotomy without reverse insertion of a ureteral catheter

    Procedure: PCNL without reverse insertion of a ureteral catheter

  • No intervention
    Conventional

    Percutaneous nephrolithotomy with reverse insertion of a ureteral catheter

Interventions

  • ProcedurePCNL without reverse insertion of a ureteral catheter

    The ureteral catheter was not retrograde inserted during PCNL

06

What researchers measure

Primary outcomes

  1. Rate of fever

    Fever was defined as axillary temperature greater than 38.5 ° C.

    Time frame: From the day of surgery to the day of discharge, up to 2 weeks.

  2. White blood cell count change value

    The change value of White blood cell count between preoperative and postoperative

    Time frame: Day 2 before surgery、hour 3 after the surgery

  3. Neutrophils granulocyte change value

    The change value of Neutrophils granulocyte between preoperative and postoperative

    Time frame: Day 2 before surgery、hour 3 after the surgery

  4. Hemoglobin change value

    The change value of Hemoglobin between preoperative and postoperative

    Time frame: Day 2 before surgery、hour 3 after the surgery

  5. Hematocrit change value

    The change value of Hematocrit between preoperative and postoperative

    Time frame: Day 2 before surgery、hour 3 after the surgery

  6. Rate of renal subcapsular hematoma

    The proportion of postoperative renal subcapsular hematoma in all patients

    Time frame: Day 2 after the surgery

  7. Serum creatinine change value

    The change value of Serum creatinine between preoperative and postoperative

    Time frame: Day 2 before surgery、Hour 3 after the surgery

  8. visual analog scale (VAS)pain score

    0: no pain; Less than 3 points: mild pain, tolerable; 4 points to 6 points: the patient's pain and affect sleep, still tolerable; 7-10: Patients have increasing pain, pain is unbearable, affect appetite, affect sleep.

    Time frame: Hour 2 after the surgery

  9. Rate of hydrothorax

    Hydrothorax appeared on the surgical side.

    Time frame: Day 2 after the surgery

Secondary outcomes

  1. Stone free rate

    Residual stone less than 4mm in diameter was considered to have been cleared.

    Time frame: Day 2 after the surgery

  2. Operation time

    Operation time was defined as the time required from the surgeon's handwashing to the completion of surgical incision suture

    Time frame: During the procedure

  3. length of hospital stay

    Length of hospital stay indicated the number of days between the operation date and discharge date

    Time frame: 2 weeks after surgery

  4. Medical costs

    All medical expenses incurred to treat stones.

    Time frame: 2 weeks after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data will be made available to other researchers after the study Report are published.

Supporting information: Study protocol, Informed consent form

Time frame: One year after the study report was published,but the duration is uncertain.

Access criteria: When proper editing or review requirements are met, the study data will be available from the study manager after the study is completed.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05598671
Lead sponsor
The First Affiliated Hospital of University of South China
Responsible party
Li Mingyong, MD (Associate professor, The First Affiliated Hospital of University of South China) — Principal investigator
First posted
Oct 28, 2022
Start date
Nov 3, 2022
Primary completion
Nov 1, 2024 (estimated)
Completion
Feb 1, 2025 (estimated)
Last update
Feb 28, 2024

Study contacts

Mingyong Li, MD.
Contact
myli1123@126.com
137-8648-4606 ext. +86
Mingyong Li, MD.
study director · the First Affiliated Hospital of the University of South China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion